INTRODUCTION
Due to the attention garnered by the emergence of CA-MRSA and the subsequent spread of common CA-MRSA strains (e.g., USA300 isolates) into health care settings, recent research has focused on understanding the virulence mechanisms enabling these isolates to be so successful. Meanwhile, strain types that more commonly cause health care-associated MRSA (HA-MRSA) infections, which have been around much longer and which have remained more confined to hospital settings, have not received as much basic research attention, despite the frequency with which they are responsible for infections. The most common HA-MRSA strains are those of the USA100 pulsed-field gel type, which have a staphylococcal cassette chromosome mec (SCCmec) type II island, are spa type 2, and are often multidrug resistant (6, 7). In 2005 and 2006, 53.2% of the MRSA samples from patients with invasive disease were of the USA100 genotype (8). In 2009 and 2010, 37% of nasal MRSA isolates and 36% of blood culture MRSA isolates from one study were USA100 (7). In a related study, Richter et al. found that USA100 isolates represented 16.8% of MRSA isolates and were the most common blood culture MRSA isolates (9). In a more recent comprehensive meta-analysis, USA100 MRSA levels were found to have remained fairly steady from 2005 to 2013, ranging from 21 to 25% of MRSA collections, second only to the USA300 isolates in each time frame (10).
In comparison to USA300 isolates, the USA100 isolates demonstrate in vitro resistance to more antibiotic classes, such as fluoroquinolones, macrolides, and lincosamides (9). Additionally, most
In all
FIG 1
The USA100 agr type II system. (A) Schematic of the
Our goal in this study was to better understand the contribution of the agr-II system to USA100 MRSA antibiotic resistance and virulence. We obtained clinical USA100 isolates that represent spa type 2 and SCCmec type II and selected those that had a functional agr system, as predicted from toxin production. There is some evidence that agr contributes to antibiotic resistance (18), and since USA100 isolates are some of the most resistant isolates, we reasoned that agr-II might influence resistance levels. Since agr is a major contributor to the virulence of other MRSA isolates, we predicted that it would be important for toxin and exoenzyme production, as well as infection potential.
RESULTS
Bacterial strain selection and construction of agr mutants.
A total of 526 pulsed-field gel electrophoresis- and spa-typed
HA-MRSA strains are known to pick up agr locus variants that result in dysfunction more commonly than CA-MRSA strains (22, 23). Since the goal was to study USA100 isolates with an intact agr system, we assessed the alpha-toxin activity of the 67 candidates as a proxy for agr function. The results of a rabbit red blood cell lysis assay serve as an indicator of alpha-toxin activity (24), and we performed this assay with the candidates and compared the results to those for USA300 strain LAC as a control (Fig. 1C). Eight USA100 isolates that had robust alpha-toxin production (marked in red in Fig. 1C; Table 1), suggesting that they had intact and functional agr type II systems, were selected. To inactivate the agr locus, the well-known Δagr::TetM (hereafter called Δagr) cassette was crossed into each strain, and the mutation was confirmed. An additional eight strains that had lower levels of alpha-toxin production (marked in green in Fig. 1C; Table 1) were selected for comparison. Table 2 summarizes the constructed USA100 wild-type (WT) and agr null strain pairs.
TABLE 1
Characteristics of USA100 isolates selected for studya
Study | Source | spa type | SCCmec
| PVL | % of LAC |
---|---|---|---|---|---|
111 | Blood | t002 | II | Negative | 73.8 |
103 | Blood | t002 | II | Negative | 51.5 |
116 | Blood | t002 | II | Negative | 177.6 |
132 | Blood | t002 | II | Negative | 70.9 |
134 | Blood | t002 | II | Negative | 55.9 |
139 | Blood | t002 | II | Negative | 51.1 |
333 | Blood | t002 | II | Positive | 123 |
399 | Blood | t002 | II | Positive | 102 |
119 | Blood | t002 | II | Negative | 8.7 |
375 | Blood | t002 | II | Positive | 13.5 |
191 | Blood | t088 | II | Negative | 21.5 |
148 | Blood | t002 | II | Negative | 22.9 |
155 | Blood | t002 | II | Negative | 23.6 |
298 | Blood | t002 | II | Positive | 23.6 |
412 | Blood | t002 | II | Positive | 30.3 |
107 | Blood | t002 | II | Negative | 35.7 |
a
PVL, Panton-Valentine leukocidin; RBC, red blood cell.
TABLE 2
Nomenclature for the USA100 wild-type and agr mutant isolates studied
Strain | Study clinical | Reference |
---|---|---|
AH1263 | LAC (Erm sensitive)a | 51 |
AH843 | MW2 | 52 |
AH2759 | LAC/pAmiAgrP3 | 53 |
AH1677 | LAC/pDB59 | 27 |
AH3185 | MW2/pAmiAgrP3 | This work |
AH1747 | MW2/pDB59 | 27 |
AH4489 | 103 | This work |
AH4541 | 103 Δagr | This work |
AH5445 | 103/pDB59 | This work |
AH2617 | 111 | This work |
AH2618 | 111 Δagr | This work |
AH5510 | 111/pDB59 | This work |
AH4490 | 116 | 31 |
AH4542 | 116 Δagr | This work |
AH5446 | 116/pDB59 | This work |
AH4390 | 116/pAmiAgrP3 | This work |
AH4491 | 132 | 31 |
AH4543 | 132 Δagr | This work |
AH5492 | 132/pDB59 | This work |
AH4492 | 134 | This work |
AH4544 | 134 Δagr | This work |
AH5447 | 134/pDB59 | This work |
AH5070 | 134/pAmiAgrP3 | This work |
AH4493 | 139 | This work |
AH4528 | 139 Δagr | This work |
AH5448 | 139/pDB59 | This work |
AH4494 | 333 | This work |
AH4529 | 333 Δagr | This work |
AH5493 | 333/pDB59 | This work |
AH4495 | 399 | This work |
AH4530 | 399 Δagr | This work |
AH5299 | 412 | This work |
AH5495 | 412/pDB59 | This work |
AH5294 | 155 | This work |
AH5494 | 155/pDB59 | This work |
AH5300 | 107 | This work |
AH5453 | 107/pDB59 | This work |
AH5298 | 375 | This work |
AH5452 | 375/pDB59 | This work |
AH5296 | 298 | This work |
AH5451 | 298/pDB59 | This work |
AH5295 | 191 | This work |
AH5450 | 191/pDB59 | This work |
AH5297 | 119 | This work |
AH5293 | 148 | This work |
a
Erm, erythromycin.
USA100 agr system kinetics.
To compare the agr activation kinetics in USA100 isolates to that in other
FIG 2
USA100 agr activation kinetics. (A) USA300 strain LAC, USA400 strain MW2, and USA100 strains 116 and 134 containing an agr P3-lux reporter were grown for 15 h, and the optical density at 600 nm and luminescence were measured. (B) USA300 strain LAC, USA400 strain MW2, and USA100 strains 116 and 134 containing the agr P3-YFP reporter (pDB59) were grown for 24 h, and the optical density at 600 nm and the fluorescence were measured. (C) Fluorescence measurements of all USA100 strains used in the study containing the agr P3-YFP reporter (pDB59) after 14 h of growth. Statistical significance was determined using Student's t test. ****, P < 0.0001. RFU, relative fluorescence units.
While the agr P3-lux reporter is powerful and provides useful kinetic analysis, it is somewhat challenging to use genetically, as some
Next, we compared the 13 USA100 YFP reporter strains to the CA-MRSA controls, selecting the 14-h time point to assess the maximal activity of the reporter (Fig. 2C). The activity of the USA300 reporter was consistently and significantly higher than that of all others at this time point. Some of the high-alpha-toxin-producing USA100 isolates (strains 111 and 116) maintained a high agr output, while some of the low-toxin producers (strains 191 and 375) had a low agr output or lacked agr function (strains 119 and 148). However, there was a lot of strain-dependent variability that was not always consistent (Fig. 2C). In general, the CA-MRSA strains are known to have a robust agr system function and to produce high levels of RNAIII (14), and within the CA-MRSA group, the USA300 lineage has an exceptionally strong agr function that can outperform that of isolates of other lineages, such as USA400 isolates (28). Taken together, USA100 isolates have agr kinetics of activation similar to that of CA-MSRA isolates but achieve a lower overall maximal output.
USA100 virulence factor production.
It is known that the agr system regulates hemolysins and exoenzymes that are essential for
FIG 3
Contribution of agr to USA100 virulence factor expression. (A) Hemolytic zones at 24 h, measured as the diameter (in millimeters) minus the colony size (in millimeters) for each pair. (B) Proteolytic activity, expressed as the equivalent of a trypsin standard. The WT demonstrated more hemolysis and proteolysis than the Δagr mutant in the strain pairs, but two Δagr mutants (strains 116 and 399) did show low levels of hemolysis. Statistical significance was determined using Student's t test. ****, P < 0.0001; ***, P < 0.001; **, P < 0.01.
Secreted enzymes are another major class of
The USA100 agr system contributes to skin infection.
Numerous studies have demonstrated that the agr system of CA-MRSA USA300 strains contributes to skin infection in animal models (35–39), but its contribution is less clear in the HA-MRSA USA100 isolates. Specifically, we chose the strain pairs of the two strains 116 and 399 as USA100 strain sets that exhibited a high level of hemolysis both for the WT and at the background level for the Δagr mutant (Fig. 3A). Using an intradermal infection model that we have previously used to assess MRSA skin virulence (36–38, 40, 41), the lesion sizes were dramatically bigger in mice challenged with the 116 WT strain than in mice challenged with the Δagr mutant over time (Fig. 4A). A similar pattern was observed with the 399 strain, with the lesions in the mice challenged with the WT being consistently larger than those in the mice challenged with the Δagr mutant (Fig. 4B). Pictures of the gross lesion pathology (Fig. 4C) at 5 days and measurement of these lesion sizes (Fig. 4D) confirmed this phenotype. Consistent with this, the USA100 WT-challenged mice experienced more weight loss over 7 days than the mutant strain-challenged mice (Fig. 4E and F). Despite each of these strains having significant background levels of hemolysis on sheep blood (Fig. 3A), the contribution of this to a skin lesion was minimal. Taken together, these data suggest that when the agr system is intact, higher levels of virulence factors are expressed, resulting in a greater systemic effect of infection, in addition to a larger abscess size.
FIG 4
Role of agr in USA100 skin infections. (A, B) Comparison of lesion size for mice inoculated with the strain 116 (A) and 399 (B) WT and Δagr mutant strain pairs over 1 week (n = 5 for each group). (C) Photographs of ventral skin lesions 5 days after inoculation with WT and Δagr mutant strains. Note the smaller areas of dermal necrosis resulting from infection with the Δagr mutants. (D) Comparison of lesion size between WT and Δagr mutant isolates 5 days after intradermal injection of mice (n = 5 for each group). (E, F) Comparison of weight loss (expressed as a percentage of the starting weight) in mice which underwent intradermal injections of the strain 116 (E) and 399 (F) WT and Δagr isolates. Statistical significance was determined using Student's t test. **, P < 0.01; *, P < 0.05.
Contribution of agr to antibiotic resistance.
Previous studies have suggested a potential difference in the survival of MRSA WT strains and Δagr strains when exposed to antibiotics (18, 23, 42). As shown in Table 3, we tested the USA100 strain pairs for resistance to 13 common antibiotics using Etest strips. Except for the tetracycline resistance due to the Δagr::TetM construct, there was no significant difference in antibiotic resistance between the USA100 WT and each paired Δagr mutant. This matches previous reports of the results of MIC testing of diverse
TABLE 3
MICs of USA100 strain pairs
Strain | MICa
(μg/ml) | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
FOX | CLI | DAP | ERY | GEN | LVX | LZD | OXA | Q-D | RIF | TET | SXT | VAN | |
103 WT | 96 | 0.094 | 0.25 | >256 | 0.25 | >32 | 1.5 | >256 | 0.5 | 0.012 | 0.19 | 0.064 | 1.5 |
103 Δagr | 48 | 0.094 | 0.125 | >256 | 0.25 | >32 | 2 | >256 | 0.5 | 0.012 | 24 | 0.064 | 1 |
111 WT | 12 | > 256 | 0.38 | >256 | 0.38 | >32 | 3 | >256 | 1 | 0.016 | 0.5 | 0.094 | 2 |
111 Δagr | 32 | >256 | 0.19 | >256 | 0.5 | >32 | 3 | 192 | 1 | 0.012 | 32 | 0.064 | 1.5 |
116 WT | 48 | 0.125 | 0.19 | >256 | 0.38 | >32 | 1.5 | 64 | 0.38 | 0.008 | 0.25 | 0.094 | 1 |
116 Δagr | 24 | 0.094 | 0.125 | >256 | 0.5 | >32 | 1.5 | 24 | 0.38 | 0.008 | 24 | 0.094 | 1 |
132 WT | >256 | 0.125 | 0.19 | >256 | 0.38 | >32 | 2 | >256 | 1.5 | 0.012 | 0.38 | 0.094 | 1.5 |
132 Δagr | >256 | 0.125 | 0.25 | >256 | 0.75 | >32 | 2 | >256 | 0.75 | 0.012 | 48 | 0.094 | 1.5 |
134 WT | >256 | 0.125 | 0.25 | >256 | 0.38 | >32 | 2 | >256 | 0.5 | 0.012 | 0.19 | 0.094 | 2 |
134 Δagr | >256 | 0.125 | 0.25 | >256 | 0.38 | >32 | 1.5 | >256 | 0.5 | 0.012 | 24 | 0.094 | 2 |
139 WT | >256 | >256 | 0.38 | >256 | 0.38 | >32 | 3 | >256 | 1 | 0.012 | 0.38 | 0.094 | 2 |
139 Δagr | >256 | >256 | 0.38 | >256 | 0.5 | >32 | 3 | >256 | 0.75 | 0.012 | 24 | 0.094 | 1.5 |
333 WT | 192 | 0.125 | 0.38 | 256 | 0.5 | >32 | 2 | >256 | 0.5 | 0.012 | 0.5 | 0.094 | 2 |
333 Δagr | 96 | 0.125 | 0.38 | >256 | 0.38 | >32 | 2 | >256 | 0.5 | 0.012 | 16 | 0.094 | 1.5 |
399 WT | >256 | >256 | 0.5 | >256 | 0.75 | 8 | 1.5 | >256 | 0.75 | 0.012 | 0.19 | 0.19 | 2 |
399 Δagr | >256 | >256 | 0.38 | >256 | 0.75 | 6 | 1.5 | >256 | 0.75 | 0.012 | 24 | 0.19 | 2 |
a
MICs are based on the Etest for the USA100 wild-type and agr mutant isolate pairs. Overall, there was no difference in antibiotic resistance, as determined by the use of Etest strips, with the exception of resistance to tetracycline, which was as expected, since the tetracycline resistance cassette was incorporated into the genome of each agr mutant as part of mutant construction. FOX, cefoxitin; CLI, clindamycin; DAP, daptomycin; ERY, erythromycin; GEN, gentamicin; LVX, levofloxacin; LZD, linezolid; OXA, oxacillin; Q-D, quinupristin-dalfopristin; RIF, rifampin; TET, tetracycline; SXT, trimethoprim-sulfamethoxazole; VAN, vancomycin.
Since survival and stress assays have shown different behaviors for strains with a defective agr gene, we performed more careful growth curves for each USA100 strain pair with cefoxitin, clindamycin, daptomycin, and vancomycin. For cefoxitin at levels below the MIC (∼16 μg/ml), some differences in growth were noted. The Δagr mutant and the WT in the strain 103 strain pair demonstrated statistically significantly different inhibitory growth (Fig. 5A), and the two strains in the strain 333 strain pair grew in a fashion comparable to that for the two strains in the strain 103 strain pair (data not shown). For the strain 111 strain pair, a similar and even more pronounced pattern was apparent, with the growth of the Δagr mutant dramatically lagging behind that of the WT (Fig. 5B). The growth of the WT and the Δagr mutant in the rest of the strain pairs exhibited few differences in the presence of cefoxitin (representative plots for strains 134 and 139 are shown in Fig. 5C and D, respectively.
FIG 5
Growth of USA100 strains in the presence of a sub-MIC of cefoxitin. (A, B) The strain 103 (A) and 111 (B) WT strains demonstrated growth superior to that of the paired Δagr mutants when exposed to cefoxitin, suggesting that a functional agr system in these strains contributes to survival under antibiotic stress. (C, D) Growth curves for representative strains 134 (C) and 139 (D) in which no differences in growth were observed between each of the strains in the strain pairs tested with the same concentration of cefoxitin.
The largest differences between the pairs of USA100 strains were observed in the presence of vancomycin. At 2 μg/ml, the upper limit for the MIC (Table 3), the growth of the Δagr mutant lagged behind that of the WT for each of the strain 132, 134, 139, 333, and 399 strain pairs (the results for the strain 132, 134, 139, and 399 strain pairs are shown in Fig. 6A to D, respectively). The two strains in each of the strain 103 and 111 strain pairs did not have any obvious differences in their growth curve patterns, while the two strains in the strain 116 strain pair grew in an inconsistent manner (data not shown). Additional growth curves were performed with clindamycin (32 μg/ml) and daptomycin (20 μg/ml), and in each case, no major differences in growth between the WT and the Δagr mutant were observed.
FIG 6
Growth of USA100 strains in the presence of a sub-MIC of vancomycin. WT strains 132 (A), 134 (B), 139 (C), and 399 (D) demonstrated growth superior to that of the paired Δagr mutants when exposed to vancomycin at 2 μg/ml. For at least these strains tested, a functional agr system contributes to improved survival in the presence of vancomycin.
DISCUSSION
The agr peptide quorum-sensing system is a well-described virulence regulator of CA-MRSA (14). In this study, our goal was to understand the contribution of agr to the virulence and antibiotic resistance of clinical HA-MRSA isolates, specifically, those of the USA100 group, which have a more divergent agr type II system and which make an AIP-II signal (Fig. 1). Overall, we found that hemolysin and exoenzyme production among the USA100 isolates was dependent on the agr system, with some strain-specific exceptions, and the USA100 isolates triggered dermonecrosis in a murine skin infection model in an agr-dependent manner. The contribution of agr to USA100 antibiotic resistance was limited in terms of MIC levels, but surprisingly, many of the agr mutants exhibited less tolerance to vancomycin than their WT counterparts.
The agr type II system is the most divergent from the common type I system in terms of sequence and signal structure (Fig. 1B). Despite the variance, the kinetics and behavior of the regulatory system in USA100 isolates shared many similarities to those published for laboratory strains and CA-MRSA. The agr activation profile between USA100 and CA-MRSA isolates was similar in timing, although it was weaker in overall output in USA100 isolates (Fig. 2). However, the size of the lesions in a skin infection model correlated well with those that we have observed with USA300 strains (36–38, 40), which could be due to our selection of USA100 isolates with higher alpha-toxin activity (Fig. 1C). Some USA100 agr mutants showed extensive background hemolysis, and in the case of strain 399, this could have been due to an intact sequence for hlb, encoding β-hemolysin (31). However, these results were not reproducible in the strain 116 strain pair, suggesting that background hemolysis is potentially due to another factor. Similarly, there was a surprising level of background protease activity in many of the USA100 Δagr mutants. The reason for this is not clear, but it could be due to variance in aureolysin (Aur) metalloprotease activity. Aur is one of the primary casein-cleaving enzymes (43) and is under only limited agr regulatory control (44). Therefore, the background casein cleavage in Δagr mutants (Fig. 3B) could be due to low levels of Aur production.
Our study also aimed to determine whether or not the agr system is involved in USA100 antibiotic resistance. There are previous data to suggest that the agr system may have a role in altering antibiotic resistance patterns, as evidenced by the increased survival of agr mutants when exposed to antibiotics (18, 23) and also the development of vancomycin-intermediate resistance (vancomycin-intermediate
As MRSA continues to cause infections worldwide, there is a need to understand both the virulence and resistance mechanisms of the common CA-MRSA strains and the underappreciated impact of HA-MRSA. Among the HA-MSRA strains, strains in the USA100 group are the most common and are known to be highly antibiotic resistant, and they continue to represent a significant burden to the health care system. Our work shows that the virulence properties of the agr type II system largely parallel those of the type I system, but the contribution to antibiotic resistance is less clear and in need of further investigation. Previous work has shown that blocking the agr system could be a potential target for reducing the severity of infection (36, 38, 40), and this could be applied to the treatment of USA100 infections. With the high level of antibiotic resistance in these strains and the ongoing interest in antibiotic stewardship (46), the development of new approaches to treat multidrug-resistant infections is important.
MATERIALS AND METHODS
USA100 strains.
The MRSA strains used in this study had previously been isolated from patients participating in surveillance studies coordinated by the University of Iowa Molecular Epidemiology Laboratory. These strains included both colonizing strains isolated from the nasopharynx and invasive strains, mostly from blood samples.
agr mutant construction.
The Δagr::TetM construct (47) was created by crossing Δagr::TetM by bacteriophage transduction as previously described (48). Successful transduction of the tetracycline resistance cassette was confirmed by DNA PCR. Chromosomal DNA was purified using a Qiagen PureGene kit along with a modified manufacturer protocol. DNA PCR was then performed using Crimson Taq DNA polymerase along with RNAIII downstream primer 5′-GTATAAATAAGAAGCGCCCGAAATA-3′ and agrA downstream primer 5′-CCAGCTATACAGTGCATTTGCTAGT-3′, with the expected product size for the wild type being 3,823 bp. Deletion of the agr operon and insertion of the tetracycline resistance cassette were confirmed after gel electrophoresis, which demonstrated a shorter product in the agr knockout strains, as expected.
Luminescence reporters and assay.
The agr P3-lux reporter plasmid pAmiAgrP3 (49) was purified from restriction-negative
Fluorescence reporters and assay.
The agr reporter plasmid pDB59 was transduced from restriction-negative
Alpha-toxin lysis assay.
Hemolysis assay.
To test the hypothesis of agr system control of virulence factor expression, hemolysis assays were performed. Each WT strain and agr knockout strain pair was plated on sheep blood agar and incubated overnight at 37°C; single colonies were subcultured in TSB and again incubated overnight at 37°C. Each WT and agr mutant culture was then diluted 1:100 in TSB and grown to reach an OD600 of 3 (approximately 3 to 4 h). Triplicate samples were grown for each strain pair. Subsequently, three samples were plated for each WT and mutant strain on sheep blood agar; each sample contained 2 μl of the culture described above. The samples were allowed to dry and were then incubated for 24 h at 37°C. At 24 h, the diameter of each bacterial colony and the diameter of hemolysis were measured with calipers. These measurements were taken again at 48 h, after the plates were allowed to incubate at 37°C for an additional 24 h. A total of 9 replicates were performed for each WT strain and its paired agr mutant strain.
Protease assay.
Protease assays were completed to further test the hypothesis of agr control of virulence factor expression. These experiments were performed with a Pierce fluorescent protease assay kit (Thermo Scientific), which assesses protease activity using fluorescence resonance energy transfer (FRET). For these assays, each WT and mutant strain was cultured overnight in TSB. Each of these cultures was then diluted 1:100 in TSB and grown to an OD600 of 1.5. One milliliter of culture at an OD600 of 1.5 for each WT and mutant sample was centrifuged at 13,000 × g for 1 min. One hundred microliters of the supernatant was transferred to a 96-well plate in triplicate for each wild type and mutant pair; 100 μl of a working reagent containing fluorescent-labeled casein was then added to each well, and the plates were allowed to incubate for 1 h, at which time the plates were analyzed in a fluorescent plate reader (Tecan Infinite 200) at wavelengths of between 485 and 538 nm. Tosylsulfonyl phenylalanyl chloromethyl ketone-treated trypsin (0.5 μg/ml) was used to generate a standard curve, which was then used to calculate protease activity for casein as a trypsin equivalent for each WT and mutant strain. Biological and technical replicates were performed, for a total of 9 data points for each WT and mutant isolate.
Murine infection model.
Murine models were used to test the virulence of both the WT and agr mutant strains as we previously reported (36–38, 40). Cultures were grown overnight at 37°C in a shaking incubator set at 200 rpm from frozen glycerol stocks for two selected wild-type and agr mutant strain pairs (strains 116 and 399) in 5 ml of TSB. Subcultures were prepared to a total volume of 350 ml, consisting of 34.65 ml of TSB and 350 μl of an overnight culture, and then grown to an OD600 of 0.5 at 37°C in a shaking incubator at 200 rpm. Ten milliliters of this culture was then added to 40 ml of Dulbecco’s phosphate-buffered saline (DPBS) and centrifuged at 3,500 rpm for 10 min. The pelleted cells were then resuspended in sterile saline to reach a concentration of 2 × 107 CFU/50 μl and placed on ice. Five BALB/c mice were used to test each strain, resulting in the use of 20 mice in total. Mice were anesthetized with 1 to 5% isoflurane. The abdominal skin of each mouse was shaven with a microtome blade; the mice were then labeled, weighed, and prepped for sterile injection. Insulin syringes were used to intradermally inoculate each mouse with 50 μl of a specified
Determination of MIC and antibiotic resistance patterns.
Comparison of antibiotic resistance patterns was performed using Etest strips (bioMérieux USA) to determine the MICs of cefoxitin, clindamycin, daptomycin, erythromycin, gentamicin, levofloxacin, linezolid, oxacillin, quinupristin-dalfopristin, rifampin, tetracycline, trimethoprim-sulfamethoxazole, and vancomycin. Triplicate testing for each isolate (the wild-type and null mutant isolates) was performed per the manufacturer’s protocol, and a methicillin-sensitive
To examine more subtle differences between these isolates in the presence of selected antibiotics, growth curves were performed for all strain pairs. The antibiotics selected for these studies were cefoxitin, clindamycin, daptomycin, and vancomycin. The WT and agr mutant strains were cultured overnight in TSB at 37°C. Ninety-six-well plates were prepared with serially diluted concentrations of antibiotic added to TSB. For each antibiotic, seven different concentrations were tested; in addition, one control sample without antibiotic was used for each strain. The concentrations tested for cefoxitin were 1 mg/ml, 500 μg/ml, 250 μg/ml, 125 μg/ml, 62.5 μg/ml, 31.25 μg/ml, and 15.625 μg/ml; those tested for clindamycin were 16 μg/ml, 8 μg/ml, 4 μg/ml, 2 μg/ml, 1 μg/ml, 0.5 μg/ml, and 0.25 μg/ml; those tested for daptomycin were 100 μg/ml, 50 μg/ml, 20 μg/ml, 16 μg/ml, 8 μg/ml, 4 μg/ml, and 2 μg/ml; and those tested for vancomycin were 2 μg/ml, 1 μg/ml, 0.5 μg/ml, 0.25 μg/ml, 0.125 μg/ml, and 0.625 μg/ml. Bacteria were grown from a 1:50 dilution in each well containing the respective concentration of antibiotic. These plates were then incubated at 37°C and shaken at 1,000 rpm. The absorbance (OD600) was measured by use of a microtiter plate reader (Tecan Infinite 200) starting at hour 0 and then hourly thereafter until the bacteria had reached stationary phase (8 to 10 h); measurements were then used to generate growth curves for each strain at the various antibiotic concentrations.
Statistical analysis.
GraphPad Prism (version 7) software was used to perform statistical analysis of the hemolysis, protease, and animal data. Student's t test was chosen to calculate the difference in hemolysis and proteolysis between the wild-type strain and paired agr mutant as well as the murine data comparing lesion size and weight loss between the groups challenged with the WT and the agr mutant. A P value of <0.05 was chosen to designate a statistically significant difference between values. Throughout the work, error bars represent standard deviations.
b Department of Microbiology and Immunology, University of Iowa, Iowa City, Iowa, USA
c Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, Colorado, USA
d Department of Veterans Affairs Eastern Colorado Healthcare System, Aurora, Colorado, USA
e Division of Infectious Diseases, Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA
f Division of Medical Microbiology, Department of Pathology, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA
University of Rochester
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Copyright © 2019 Grundstad et al. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Abstract
ABSTRACT
Methicillin-resistant
IMPORTANCE USA100 health care-associated MRSA isolates are highly antibiotic resistant and can cause invasive disease across all patient populations. Even though USA100 strains are some of the most frequently identified causes of infections, little is known about virulence regulation in these isolates. Our study demonstrates that the USA100 agr quorum-sensing system is important for the control of toxin and exoenzyme production and that the agr system has a key role in skin infection. In some USA100 isolates, the agr system is important for growth in the presence of low levels of antibiotics. Altogether, our findings demonstrate that the USA100 agr system is a critical regulator of virulence and that it may make a contribution to the optimal survival of these MRSA strains in the presence of antibiotics.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer